 BOSTON--BUSINESS WIRE--- KRTX--Karuna Therapeutics, Inc. NASDAQ: KRTX, a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that data from the Phase 3 EMERGENT-2 trial of KarXT in schizophrenia will be shared at the 35th European College of Neuropsychopharmacology ECNP Congress, to be held October 15-18, 2022, in Vienna, Austria. A poster presentation and symposium will incl 